Biopharmaceutical and Biomedicine Market, by Product Type (Biopharmaceutical (Monoclonal Antibodies, Vaccines, Recombinant Human Insulin, Human Growth Hormone, Erythropoietin, Interferon, Colony Stimulating Factor, Blood Factors, Fusion Protein, and Other

Biopharmaceutical and Biomedicine Market, by Product Type (Biopharmaceutical (Monoclonal Antibodies, Vaccines, Recombinant Human Insulin, Human Growth Hormone, Erythropoietin, Interferon, Colony Stimulating Factor, Blood Factors, Fusion Protein, and Others), Nanomedicine, Cell & Gene Therapy, Bioinformatics, and Molecular Enzymes & Kits), by Application (Therapeutics, Diagnostics, and Research and Development), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

A biopharmaceutical (biological or biologic), which consists of sugars, proteins, nucleic acids, living cells, or tissues, is a medicinal product semi-synthesized from biological sources such as humans, animals, or microorganisms. Biopharmaceuticals has emerged as one of the key segments with immense growth potential in the healthcare sector. Rising demand for effective treatment of diseases and rise in per capita healthcare expenditure has led to double digit revenue growth for market players in the recent past.

The biopharmaceutical and biomedicine market is expected to gain further traction, with evolving treatment options and rapid technological innovation such as cell therapy and regenerative medicines. Fewer side effects, high effectiveness and potent action, and ability to cure the disease rather than treating it are some of the major advantages of biopharmaceutical and biomedicine drugs. Currently, biopharmaceuticals accounts for over one-fifth of pharmaceutical market, and this percentage share of biopharmaceutical is expected to increase, owing to its advantages compared to totally synthesized pharmaceutical drugs.

Market Dynamics

Increasing adoption of inorganic strategies by key players in market such as acquisitions is expected to drive market growth over the forecast period. For instance, in May 2022, GSK plc, a multinational pharmaceutical company, announced that it had entered into a definitive agreement to acquire Affinivax, Inc., a clinical-stage biopharmaceutical company. Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. The acquisition will further strengthen the vaccines research & development pipeline of GSK plc and broaden its existing scientific footprint in Boston, U.S.

Key features of the study:

• This report provides in-depth analysis of the global biopharmaceutical and biomedicine market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global biopharmaceutical and biomedicine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amgen Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Pfizer Inc., Sanofi, Eli Lilly and Company, AbbVie Inc., Novo Nordisk A/S, Bristol-Myers Squibb Company, NanoString, QIAGEN, Affimed GmbH, GSK plc., Merck KgaA, and Teva Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global biopharmaceutical and biomedicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biopharmaceutical and biomedicine market

Detailed Segmentation:

• Global Biopharmaceutical and Biomedicine Market, By Product Type:
• Biopharmaceutical
• Monoclonal Antibodies
• Vaccines
• Recombinant Human Insulin
• Human Growth Hormone
• Erythropoietin
• Interferon
• Colony Stimulating Factor
• Blood Factors
• Fusion Protein
• Others
• Nanomedicine
• Cell & Gene Therapy
• Bioinformatics
• Molecular Enzymes & Kits
• Global Biopharmaceutical and Biomedicine Market, By Application:
• Therapeutics
• Diagnostics
• Research and Development
• Global Biopharmaceutical and Biomedicine Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Amgen Inc.
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Hoffmann-La Roche Ltd
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Sanofi
• Eli Lilly and Company
• AbbVie Inc.
• Novo Nordisk A/S
• Bristol-Myers Squibb Company
• NanoString
• QIAGEN
• Affimed GmbH
• GSK plc.
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.